Hypertrophic Cardiomyopathy, HCM
Conditions
Interventions
Observation group:None
Sponsors
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients meet the diagnostic criteria for HCM according to the 2024 AHA/ACC Guideline for the Management of Hypertrophic Cardiomyopathy, i.e., cardiac magnetic resonance (CMR) shows maximum wall thickness (MWT) =15 mm in any left ventricular segment at end-diastole, or =13 mm in those with a clear family history of HCM, after excluding other causes of myocardial hypertrophy (e.g., hypertension, aortic stenosis); 2.Age between 18 and 80 years; 3.Patients have complete and traceable key diagnostic and treatment records in the research center's information system available for extraction and analysis; 4.Patients clearly understand the purpose and requirements of the study and voluntarily sign informed consent or meet the criteria for waiver of consent;
Exclusion criteria
Exclusion criteria: 1.Uncontrolled hypertension, moderate or severe valvular heart disease, congenital heart disease, myocardial infarction, or angiographically confirmed significant epicardial coronary artery stenosis; 2.Confirmed diagnosis of HCM phenocopies, such as Anderson-Fabry disease, Danon disease, or cardiac amyloidosis; 3.Prior septal reduction therapy (including surgical septal myectomy or alcohol septal ablation); 4.Contraindications to CMR examination (e.g., incompatible pacemaker/implantable cardioverter-defibrillator [ICD], severe claustrophobia, severe renal insufficiency [eGFR < 30 mL/min/1.73m²]), or inability to tolerate supine examination due to severe heart failure; 5.Poor CMR image quality (e.g., severe motion artifacts, inability to perform myocardial strain analysis or late gadolinium enhancement [LGE] quantitative assessment) affecting subsequent data analysis; 6.Critical clinical data (e.g., basis for diagnosis, core imaging parameters [LVEF], prognostic endpoint information) are severely missing and cannot be supplemented retrospectively;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CMR imaging features; | — |
Countries
China
Contacts
Public ContactLianming Wu
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed